GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells

Blood

Volumn 126, Issue 13, 2015, Pages 1621-1628

  Koehn, Brent H ^a   Apostolova, Petya ^b   Haverkamp, Jessica M ^c   Miller, Jeffrey S ^a   McCullar, Valarie ^a   Tolar, Jakub ^a   Munn, David H ^d   Murphy, William J ^e   Brickey, Willie June ^f   Serody, Jonathan S ^f   Gabrilovich, Dmitry I ^g   Bronte, Vincenzo ^h   Murray, Peter J ^c   Ting, Jenny P Y ^f   Zeiser, Robert ^b,i   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g WISTAR INSTITUTE   (United States)

^h UNIVERSITY OF VERONA   (Italy)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CASPASE 8; CRYOPYRIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLAMMASOME; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; CD11 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; ENZYME ACTIVITY; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY COMPLEX; IN VITRO STUDY; INFLAMMATION; LETHALITY; LONG TERM SURVIVAL; LOSS OF FUNCTION MUTATION; MIXED LYMPHOCYTE REACTION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; SURVIVAL TIME; T LYMPHOCYTE; WILD TYPE; ADOPTIVE TRANSFER; ANIMAL; CELL CULTURE; CYTOLOGY; GRAFT VS HOST DISEASE; HUMAN; IMMUNOLOGY; PATHOLOGY; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD11; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; GRAFT VS HOST DISEASE; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; MICE; MYELOID CELLS;

EID: 84942333071     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-634691     Document Type: Article

References (43)

1. Welniak LA, Blazar BR, Murphy WJ Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007; 25(1):139-170.
2. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182(8):4499-4506.
3. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008; 222:162-179.
4. Wang D, Yu Y, Haarberg K, et al Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant. 2013; 19(5): 692-702.
5. Haverkamp JM, Smith AM, Weinlich R, et al Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014; 41(6):947-959.
6. Brunstein CG, Miller JS, Cao Q, et al Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011; 117(3): 1061-1070.
7. Peranzoni E, Zilio S, Marigo I, et al Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010; 22(2): 238-244.
8. Highfill SL, Rodriguez PC, Zhou Q, et al Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010; 116(25):5738-5747.
9. Markey KA, MacDonald KPA, Hill GR The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood. 2014; 124(3):354-362.
10. Holtan SG, Pasquini M, Weisdorf DJ Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014; 124(3):363-373.
11. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014; 124(3): 374-384.
12. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012; 12(6):443-458.
13. Schroder K, Tschopp J. The inflammasomes. Cell. 2010; 140(6):821-832.
14. Lu A, Magupalli VG, Ruan J, et al Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell. 2014; 156(6):1193-1206.
15. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009; 27:229-265.
16. Jankovic D, Ganesan J, Bscheider M, et al The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. 2013; 210(10): 1899-1910.
17. Bruchard M, Mignot G, Derangère V, et al Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013; 19(1):57-64.
18. O'Sullivan BJ, Thomas HE, Pai S, et al IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. J Immunol. 2006; 176(12):7278-7287.
19. Mariathasan S, Newton K, Monack DM, et al Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004; 430(6996):213-218.
20. Reese TA, Liang HE, Tager AM, et al Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature. 2007; 447(7140):92-96.
21. Lechner MG, Liebertz DJ, Epstein AL Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010; 185(4):2273-2284.
22. Hippen KL, Harker-Murray P, Porter SB, et al Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood. 2008; 112(7):2847-2857.
23. Zhou Z, French DL, Ma G, et al Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells. 2010; 28(3): 620-632.
24. Li Y, Tu Z, Qian S, et al Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. J Immunol. 2014; 193(5):2127-2134.
25. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-174.
26. Chou HS, Hsieh CC, Yang HR, et al Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011; 53(3):1007-1019.
27. Galli SJ, Borregaard N, Wynn TA Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011; 12(11):1035-1044.
28. Youn JI, Gabrilovich DI The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010; 40(11): 2969-2975.
29. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004; 76(3): 509-513.
30. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011; 11(7):802-807.
31. McCarthy PL Jr, Abhyankar S, Neben S, et al Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood. 1991; 78(8):1915-1918.
32. Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol. 2009; 131(2):298-307.
33. Barker BR, Taxman DJ, Ting JP Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol. 2011; 23(5):591-597.
34. Dinarello CA Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009; 27:519-550.
35. Reddy P, Teshima T, Hildebrandt G, et al Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003; 101(7):2877-2885.
36. Reddy P, Ferrara JLM Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med. 2003; 141(6):365-371.
37. Wilhelm K, Ganesan J, Müller T, et al Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010; 16(12): 1434-1438.
38. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997; 90(8):3204-3213.
39. Cooke KR, Gerbitz A, Crawford JM, et al LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001; 107(12):1581-1589.
40. Coll RC, Robertson AAB, Chae JJ, et al A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21(3):248-255.
41. Youm YH, Nguyen KY, Grant RW, et al The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015; 21(3):263-269.
42. Li H, Matte-Martone C, Tan HS, et al Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol. 2011; 186(1): 230-241.
43. Taylor PA, Ehrhardt MJ, Lees CJ, et al TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008; 112(8):3508-3516.